We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > AGI-134

News List

BioLineRx Doses First Patient in Solid Tumor Immunotherapy Study americanpharmaceuticalreview
September 27, 2019
BioLineRx announced dosing of the first patient in part 2 of the Phase 1/2a clinical study for AGI-134, a novel compound that evokes a direct anti-tumor response, as well as a vaccine effect, via a unique ...
BioLineRx Successfully Completes Dose-Escalation Part for AGI-134 Study americanpharmaceuticalreview
September 04, 2019
BioLineRx has successfully completed the dose-escalation part of the Phase 1/2a clinical study for AGI-134, a novel compound that evokes a direct anti-tumor response, as well as a vaccine effect...
BioLineRx Announces FDA Approval of IND Application for AGI-134 americanpharmaceuticalreview
May 08, 2019
BioLineRx announced the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AGI-134, a novel immunotherapy anti-cancer vaccine for solid tumors.